Clinical Trials Browser

Lung Neoplasms

Melanoma, Skin Neoplasms

Craniopharyngioma

Brain Neoplasms, Melanoma

Non-small Cell Carcinoma

Gastrointestinal Stromal Tumors

Thyroid Neoplasms

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Soft Tissue Neoplasms

Brain Neoplasms, Melanoma

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

Breast Neoplasms, Triple Negative Breast Neoplasms

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Advanced KRAS Positive Metastatic Colorectal Cancer

Brain Neoplasms, Melanoma

Pancreatic Neoplasms

Melanoma, Neoplasm Metastasis

Adenocarcinoma of Lung, Pancreatic Neoplasms, Colorectal Neoplasms

Multiple Myeloma, Recurrence

Brain Neoplasms, Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

Melanoma, Neoplasms

Lung Neoplasms

Colorectal Neoplasms

Gastrointestinal Stromal Tumors

Lung Neoplasms, Recurrence

Carcinoma, Non-Small-Cell Lung

Blast Crisis, Leukemia, Leukemia, Myeloid, Chronic-Phase

Biliary Tract Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Clinical Trials

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

BiniPembro

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

ENCO-BRAF

Study of MEK162 for Children With Low-Grade Gliomas

ENCEFALO

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

MEK162

SuRage-EB

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

EBRAIN-MEL

NF108-BINI

InCITe

SAFIR-ABC10

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

BRAF

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

SECOMBIT

BEPCOME-MB

QUAD01

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

CELEBRATE

Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

GMMG-BIRMA

MEMBRAINS

TAILOR

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

PREMIUM

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

MErCuRIC1

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Lorlatinib Combinations in Lung Cancer

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer

MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer